Joshua K. Sabari, MD, discusses how the dosing schedule of ifinatamab deruxtecan offers advantages in terms of simplicity and treatment adherence vs topotecan and lurbinectedin, suggesting that it may enhance the overall quality of life for patients undergoing treatment for SCLC.
Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.
Yelena Y. Janjigian, MD, highlights key takeaways and data from 2024 in the gastric and GEJ cancer field.
As oncology contemplates the potential impact of a second Donald Trump term on cancer care and research, The Cancer Letter has compiled a list of…
The use of tumor-informed circulating tumor DNA (ctDNA) testing in early-stage patients before surgery is limited mainly due to restricted tissue access and extended turnaround…
Genentech’s PI3K inhibitor inavolisib (Itovebi) dramatically increased progression-free survival (PFS) in patients with PIK3CA-mutated, hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to new…
Multiple myeloma disproportionately affects Black Americans, who are twice as likely to be diagnosed with it and its precursor, monoclonal gammopathy of undetermined significance (MGUS).…
This video presents the 5-year off-treatment analyses from the CLL14 and MURANO studies.
Below are videos of three women entrepreneurs being interviewed by Jim Pulcrano, Professor at IMD
Sacituzumab tirumotecan monotherapy demonstrated antitumor activity with a manageable safety profile in previously treated endometrial and ovarian cancers.
